Literature DB >> 29686490

Autonomic instability in a dehydrated child on guanfacine: Case report and literature review.

Elizabeth Roach-Fox1, Eva Welisch1, Amrita Sarpal1.   

Abstract

An 8-year-old girl on guanfacine extended-release (GXR) for attention-deficit/hyperactivity disorder presented with somnolence, bradycardia and hypotension during a heat wave. No overdose was suspected. She was admitted to the intensive care unit for monitoring and ongoing fluid resuscitation for hypotension. Electrocardiogram showed intermittent atrioventricular dissociation. Upon restarting the drug post-discharge, blood pressures were normal, and follow-up electrocardiograms documented asymptomatic bradycardia but no dissociation. GXR is used as monotherapy or adjunct therapy in the treatment of inattention and hyperactivity in children. No published paediatric or adult study has documented atrioventricular dissociation, bradycardia or hypotension significant enough to warrant hospital admission. This case suggests that GXR can pose a hemodynamic risk to children in the context of elevated environmental temperatures and dehydration. Clinicians should be aware of this potential complication and should counsel patients about signs and symptoms of hypotension, bradycardia, bradypnea and somnolence.

Entities:  

Keywords:  Attention-deficit/hyperactivity disorder; Drug side effects; Guanfacine; Intensive care

Year:  2017        PMID: 29686490      PMCID: PMC5905463          DOI: 10.1093/pch/pxx172

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  11 in total

1.  A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.

Authors:  L Scahill; P B Chappell; Y S Kim; R T Schultz; L Katsovich; E Shepherd; A F Arnsten; D J Cohen; J F Leckman
Journal:  Am J Psychiatry       Date:  2001-07       Impact factor: 18.112

2.  Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.

Authors:  Amaia Hervas; Michael Huss; Mats Johnson; Fiona McNicholas; Judy van Stralen; Sasha Sreckovic; Andrew Lyne; Ralph Bloomfield; Vanja Sikirica; Brigitte Robertson
Journal:  Eur Neuropsychopharmacol       Date:  2014-10-23       Impact factor: 4.600

Review 3.  Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.

Authors:  D F Connor; J Rubin
Journal:  Drugs Today (Barc)       Date:  2010-05       Impact factor: 2.245

4.  Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.

Authors:  Scott H Kollins; Frank A López; Bradley D Vince; John M Turnbow; Kimberly Farrand; Andrew Lyne; Sharon B Wigal; Thomas Roth
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-10       Impact factor: 2.576

5.  Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Floyd R Sallee; Andrew Lyne; Timothy Wigal; James J McGough
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

6.  A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Joseph Biederman; Raun D Melmed; Anil Patel; Keith McBurnett; Jennifer Konow; Andrew Lyne; Noreen Scherer
Journal:  Pediatrics       Date:  2008-01       Impact factor: 7.124

7.  Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.

Authors:  Floyd R Sallee; James McGough; Tim Wigal; Jessica Donahue; Andrew Lyne; Joseph Biederman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-02       Impact factor: 8.829

8.  A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.

Authors:  Timothy E Wilens; Brigitte Robertson; Vanja Sikirica; Linda Harper; Joel L Young; Ralph Bloomfield; Andrew Lyne; Gail Rynkowski; Andrew J Cutler
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-09-15       Impact factor: 8.829

9.  Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.

Authors:  Jeffrey H Newcorn; Mark A Stein; Ann C Childress; Sharon Youcha; Carla White; Gail Enright; Jonathan Rubin
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-08-01       Impact factor: 8.829

Review 10.  Different types of centrally acting antihypertensives and their targets in the central nervous system.

Authors:  P A van Zwieten; J P Chalmers
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.